钠–葡萄糖共转运蛋白2 (SGLT2)抑制剂,是一种新兴口服降糖药,近年来在糖尿病治疗领域展现出了显著的临床价值。除其核心功能——有效降糖外,研究表明,SGLT2抑制剂在心血管疾病的预防与管理方面也呈现出巨大的潜力,预示着更广泛的应用前景。尽管如此,对急性心肌梗死患者应用SGLT2抑制剂的研究相对较少,本文就合并2型糖尿病的急性心肌梗死应用SGLT2抑制剂的研究进展进行综述。Sodium-glucose linked transporter 2 (SGLT2) inhibitors, as a new type of oral hypoglycemic drugs, have shown significant clinical value in the field of diabetes treatment in recent years. In addition to its core function of effectively lowering blood sugar, research shows that SGLT2 inhibitors also show great potential in the prevention and management of cardiovascular diseases, indicating broader application prospects. Despite this, there are relatively few studies on the use of SGLT2 inhibitors in patients with acute myocardial infarction. This article reviews the research progress on the use of SGLT2 inhibitors in patients with acute myocardial infarction combined with type 2 diabetes.
暂无评论